Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
Restaurants get off to a quick start thanks to game-changing policies
High service charges on event ticket refunds call for further regulation
Sunday
- Subscribe
'Safe' flu vaccine hailed
Source: Agencies |
August 19, 2009, Wednesday
|
Print Edition
Print Edition
A CHINESE company has completed clinical tests on a new influenza vaccine against the H1N1 virus, which proves to be "safe and effective."
Sinovac Biotech Company, a Beijing-based pharmaceutical company, said yesterday that it was the world's first H1N1 vaccine to undergo successful testing on humans.
Researchers from the Chinese Center for Disease Control and Prevention and the National Institute for the Control of Pharmaceutical and Biological Products conducted and supervised the test work in Beijing.
"Trials show that the first dose of vaccine triggers an immune response in the human body good enough to protect against the H1N1 virus strain," said Sinovac General Manager Yin Weidong.
Yin said there had been no severe adverse reactions reported after more than 1,600 volunteers aged above three received their first inoculations last Saturday.
"The occurrence of slight adverse reactions, such as pain at the site of injection, was similar to those of seasonal flu vaccines. This means the vaccine is safe," he said.
"This will lay a good foundation for future production and use of the vaccine, once we finish evaluations and obtain approval from the State Food and Drug Administration."
Sinovac Biotech Company, a Beijing-based pharmaceutical company, said yesterday that it was the world's first H1N1 vaccine to undergo successful testing on humans.
Researchers from the Chinese Center for Disease Control and Prevention and the National Institute for the Control of Pharmaceutical and Biological Products conducted and supervised the test work in Beijing.
"Trials show that the first dose of vaccine triggers an immune response in the human body good enough to protect against the H1N1 virus strain," said Sinovac General Manager Yin Weidong.
Yin said there had been no severe adverse reactions reported after more than 1,600 volunteers aged above three received their first inoculations last Saturday.
"The occurrence of slight adverse reactions, such as pain at the site of injection, was similar to those of seasonal flu vaccines. This means the vaccine is safe," he said.
"This will lay a good foundation for future production and use of the vaccine, once we finish evaluations and obtain approval from the State Food and Drug Administration."
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
